General Information of Drug (ID: DMU54QB)

Drug Name
Treximet
Synonyms
Trexima; Naproxen mixture with sumatriptan; Naproxen sodium mixture with sumatriptan succinate; Sumatriptan mixture with naproxen;Sumatriptan succinate and naproxen sodium; Sumatriptan succinate mixture with naproxen sodium; Naproxen / sumatriptan
Indication
Disease Entry ICD 11 Status REF
Migraine 8A80 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
3
Molecular Weight 665.7
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 12
Hydrogen Bond Donor Count 4
Hydrogen Bond Acceptor Count 11
Chemical Identifiers
Formula
C32H40N3NaO9S
IUPAC Name
sodium;butanedioic acid;1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide;(2S)-2-(6-methoxynaphthalen-2-yl)propanoate
Canonical SMILES
C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)[O-].CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O.[Na+]
InChI
InChI=1S/C14H21N3O2S.C14H14O3.C4H6O4.Na/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3;1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10;5-3(6)1-2-4(7)8;/h4-5,8-9,15-16H,6-7,10H2,1-3H3;3-9H,1-2H3,(H,15,16);1-2H2,(H,5,6)(H,7,8);/q;;;+1/p-1/t;9-;;/m.0../s1
InChIKey
IGRAQVLKCQVBQA-DBQHITQZSA-M
Cross-matching ID
PubChem CID
23709079
CAS Number
811794-26-0
TTD ID
D07NJI

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Antagonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Migraine
ICD Disease Classification 8A80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 1A receptor (HTR1A) DTT HTR1A 2.18E-01 -0.11 -0.51
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021926.
2 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).